STOCK TITAN
  1. Home
  2. News
  3. NVTA

Invitae Corp - NVTA STOCK NEWS

Welcome to our dedicated news page for Invitae (Ticker: NVTA), a resource for investors and traders seeking the latest updates and insights on Invitae.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Invitae's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Invitae's position in the market.

News
Labcorp Announces Winning Bid for Select Assets of Invitae
Rhea-AI Summary
Labcorp, a global leader in laboratory services, has won the bid for select assets of Invitae, a medical genetics company. The transaction, awaiting court approval on May 6, 2024, is valued at $239 million and is expected to generate $275-$300 million in annual revenue, primarily in oncology and rare diseases testing. The deal is set to close in the third quarter of 2024, pending regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.61%
Tags
none
-
News
Invitae Enters into Agreement with Labcorp for Sale of Business
Rhea-AI Summary
Invitae, a leading medical genetics company, has entered into an agreement with Labcorp for the sale of its business. Labcorp, a global leader in laboratory services, has been selected as the winning bidder in a court-supervised sale process under Section 363 of the U.S. Bankruptcy Code. The $239 million cash bid includes the acquisition of substantially all of Invitae's assets, ensuring business continuity for customers, partners, and employees. The sale is subject to court and regulatory approvals, with completion expected in the third quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.61%
Tags
none
-
News
Invitae Publishes its Environmental, Social and Governance (ESG) Report
Rhea-AI Summary
Invitae, a leading medical genetics company, published its 2024 Environmental, Social and Governance (ESG) Report detailing its commitment to improving healthcare through genetic information. The report highlights achievements in patient access, genetic insights, product quality, and environmental sustainability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
106.67%
Tags
none
News
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
Rhea-AI Summary
Invitae (NVTA) announces new studies to be presented at the American Society of Breast Surgeons Annual Meeting, highlighting the role of machine learning in reducing variants of uncertain significance (VUS) in genetic testing for breast cancer patients. The research shows machine learning models can benefit underrepresented populations, resulting in more definitive genetic testing outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-70%
Tags
none
-
News
Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification
Rhea-AI Summary
Invitae launches Clinical Variant Modeling to reduce variants of uncertain significance, providing more definitive answers for patients. The innovative approach leverages clinical information to improve variant classification and reduce VUS, benefiting nearly 45,000 patients initially.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
none
-
News
Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Invitae (NVTA) announces estimated unaudited financial results for Q4 and FY 2023, showing revenue growth, gross profit increase, and cash burn details. Q4 revenue up 4% to $127.8 million, with GAAP gross profit at $74.1 million. FY 2023 revenue at $487.0 million, down 6% YoY, but non-GAAP gross profit increased to $254.2 million. Cash burn details and caution on unaudited data provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
earnings
News
Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting
Rhea-AI Summary
Invitae introduces Invitae Generation™, a high-quality variant detection and classification platform, at the 2024 ACMG Annual Clinical Genetics Meeting. The platform showcases the company's commitment to innovation and excellence in genetic variant testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.02%
Tags
conferences
-
News
Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process
Rhea-AI Summary
Invitae (NVTA) files for voluntary chapter 11 protection to manage costs and improve business structure. The company plans to operate using its cash on hand and continue serving customers and patients. Senior noteholders support the sale process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.67%
Tags
none
-
News
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
Rhea-AI Summary
Invitae (NVTA) announces a partnership with BridgeBio Pharma (BBIO) to advance genetics-based drug discovery for rare diseases. The collaboration aims to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs. Invitae's extensive dataset and analytical capabilities will be combined with BridgeBio's expertise in rare disease research and therapeutic development to support the development of transformative medicines for patients with rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
partnership
News
Natera Acquires Reproductive Health Assets from Invitae
Rhea-AI Summary
Natera, Inc. (NTRA) has acquired certain assets from Invitae (NVTA) related to non-invasive prenatal screening and carrier screening business. The upfront payment to Invitae was $10 million, with potential milestone payments totaling $42.5 million. Invitae will transition its customers to Natera. Natera CEO, Steve Chapman, expressed commitment to providing excellent service and supporting additional patients and providers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
acquisition
Stock NVTA logo
Invitae Corp

NYSE:NVTA

NVTA Rankings

N/A Ranked by Market Cap
#5279 Ranked by Stock Gains
N/A Ranked by Dividends

NVTA Stock Data

5.59M
284.38M
1.51%
47.96%
23.65%
Medical Laboratories
Health Care and Social Assistance
Link
US
San Francisco

About NVTA

invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. specializing in genetic diagnostics for hereditary disorders, invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. choose from our curated panels or design your own test for the same low price. today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. together we can improve healthcare for billions of people.